To appraise the clinical and cost effectiveness of olaparib within its marketing authorisation for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that have responded to platinum-based chemotherapy regimen.
 
Status In progress
Process STA pre-2018
ID number 1296

Provisional Schedule

The committee meeting scheduled for 8 January 2019 will not be taking place. A further update will be provided in due course. 21 December 2019

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group BMJ-TAG

Consultees

Companies sponsors AstraZeneca UK
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Ovacome
  Ovarian Cancer Action
  Target Ovarian Cancer
  The Eve Appeal
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety - Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups National Cancer Research Institute
  The Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
16 July 2019 Committee meeting: 2
01 July 2019 In progress, Further to previous updates, this appraisal will now be restarted and the appraisal committee will discuss this topic at their meeting on 16 July 2019.
27 February 2019 Suspended, The company has requested that the appraisal of olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy [ID1296] be paused until the outcome of the appraisal of olaparib for maintenance treatment of BRCA-mutated ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID1124] is known. We have therefore decided to suspend this appraisal for the time being. We will provide a further update in due course.
09 November 2018 - 30 November 2018 Appraisal consultation
16 October 2018 Committee meeting: 1
06 April 2018 Invitation to participate
21 February 2018 - 21 March 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
21 February 2018 In progress, ref received from DH 26/07/2017
27 July 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance